Advertisement

Antibody Prevalence of Parenterally Transmitted Viruses (HIV-1, HTLV-I, HBV, HCV) in Austrian Intravenous Drug Users

  • J. Pont
  • C. Neuwald
  • G. Salzner

Abstract

From 1985 to 1990 the sera of 372 recently imprisoned intravenous drug users (IDU) were tested for HIV-1 antibodies. The seroprevalence was 18%, males 16% and females 31%. HIV-1 seroprevalence in Austrian IDU has not increased since 1986. All sera tested for HTLV-I-antibodies were negative. The majority of the HIV-1 seropositive drug users had been infected before 1985. The reported frequency of needle sharing has decreased since 1986. Of 151 IDU tested for HCV antibodies 75% were positive for anti-HCV, 68% were positive for hepatitis B markers, 59% were positive both for HBV and HCV markers, and 13% were positive for HIV-1 antibodies. In conclusion: In Austrian IDU HIV-1 seroprevalence has not increased since 1986; HTLV-I infection has not yet entered; HCV seems to be the most frequent parenterally transmitted virus.

Keywords

Drug Addict Intravenous Drug User Needle Sharing Female Prisoner Intravenous Drug Abuser 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Arnold Th, Frietsch R: Zur AIDS-Problematik in der Drogenarbeit (1987). Suchtgefahren 4, 237–247Google Scholar
  2. De Rossi A, Dalla Gassa 0, Del Mistro A: HTLV-III and HTLV-I infection in populations at risk in the Veneto region of Italy (1986). Eur J Cancer Clin Oncol. 36, 557–559Google Scholar
  3. Esteban JI, Esteban R, Viladomin L et al: Hepatitis C virus antibodies among risk groups in Spain (1989) Lancet ii: 294–296Google Scholar
  4. Ferroni P, Geroldi D, Galli C, Zanetti AR, Carguel A: HTLV-III antibodies among Italien drug addicts. (1985) Lancet ii: 52–53Google Scholar
  5. Fuchs D, Unterweger B, Hausen A et al: Anti-HIV-1 antibodies, anti-HTLV-I antibodies and Neopterin levels in parenteral drug addicts in the Austrian Tyrol. Journal of Acquired Immune Deficiency Syndromes (1988) 1: 65–66PubMedGoogle Scholar
  6. Gradilone A, Zani G, Barillari G et al: HTLV-I and HIV infection in drug addicts in Italy. Lancet (1986) ii: 753–754CrossRefGoogle Scholar
  7. Harms G, Bienzle U, Schneider V, Bschor F: HIV-Antikörperprävalenz bei Berliner Drogenabhängigen AIFO (1987) 2: 392–393Google Scholar
  8. Heckmann W, Seyrer Y: AIDS und Drogenabhängigkeit: Stand der Dinge. Suchtgefahren (1987) 33: 337–345Google Scholar
  9. Köhler H, Lange W, Rex W, Koch MA, L’age-Stehr J: Antibodies to LAU/HTLV-III in Berlin prison inmates with risk factors for hepatitis B from 1980–1985. Proceedings of the H. International Conference on AIDS (1986) 121Google Scholar
  10. Krämer A, Goedert JJ, Blattner WA, Marcus U: No evidence of HTLV-I infection in intravenous drug abusers in West-Germany. Journal of Acquired Immunodeficiency Syndromes (1988) 1: 163–164Google Scholar
  11. Krasser C et al: Bundesgesundheitsblatt (1986) 26: 343Google Scholar
  12. Kuo G, Choo QL, Alter HJ et al: An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science (1989) 244: 362–364PubMedCrossRefGoogle Scholar
  13. Mildvan D, Des Jarlais D, Sotheran J et al: Prevalence and significance of HTLV-I in a cohort of intravenous drug users in New York. Proceedings IV. International Conference on AIDS, Stockholm (1988) abstr. 4517Google Scholar
  14. Mortimer PP, Vandervelde EM, Jesson WJ, Pereira MS, Burkhardt F: HTLV-III antibody in Swiss and English intravenous drug abusers. Lancet (1985) ii: 449–450Google Scholar
  15. Mosley JW, Redeker AG, Feinstone SM, Purcell RH: Multiple hepatitis viruses in multiple attacks of acute viral hepatitis. N Engi J Med (1977) 296: 75–78CrossRefGoogle Scholar
  16. Pont J: Untersuchungen an alkohol-und drogenabhängigen Untergebrachten hinsichtlich chronischer Lebererkrankungen. Wien Zschr Suchtforsch (1983) 6: 55–57Google Scholar
  17. Pont J, Neuwald Ch, Kunz Ch, Werdenich W:HTLV-III-Serologie, Epidemiologie und Klinik inhaftierter i.v. drogenabhängiger Männer in österreich. Wien Klin Wochenschr (1986) 98: 454–457PubMedGoogle Scholar
  18. Pont J, Neuwald Ch, Lichtenauer B, Salzner G: Keine Prävalenzzunahme von HIV-1 und HTLV-I-Antikörpern bei i.v.-Drogenabhängigen in Österreich während 1985–1988 AIFO (1989) 4: 198–201Google Scholar
  19. Püschel K, Liske K, Laufs R: Entwicklung der HIV-1-Antikörperprävalenz bei Rauschgifttoten in Berlin und Hamburg. AIFO (1988) 3: 452–454Google Scholar
  20. Reuband KH: Drogenstatistik 1986. Informationsdienst der Deutschen Hauptstelle gegen die Suchtgefahren (1987) 40–70Google Scholar
  21. Rodrigo JM, Serra MA, Aguilar E:HTLV-III antibodies in drug addicts in Spain. Lancet (1985) ii:156–157Google Scholar
  22. Sauer A, Behnken LJ, Rübsamen-Waigmann H, Brede HD, Helm EB: HIV-Infektion in der Justizvollzugsanstalt 1 Frankfurt am Main. AIFO (1987) 2: 502–507Google Scholar
  23. Tor J, Muga R, Melus R, Ginesta C, Ribera A, Foz M: HIV infection prevalence in intravenous drug abusers in Barcelona 1984–1987. European Conference on Clinical Aspects of HIV Infection, Brussels (1987) abstr. 23Google Scholar
  24. Velimirovic B: AIDS und Drogenabhängigkeit aus der Sicht des Epidemidogen. AIFO (1987) 2: 323–334Google Scholar
  25. Weiss SH, Ginzburg HM, Saxinger WC: Emerging high rates of human T-cell Lymphotropic virus type I and HIV infection among U.S. drug abusers. III. International Conference on AIDS. Washington D.C. (1987) abstr. F6.5.Google Scholar
  26. Zoulek G, Gürtler L, Eberle J, Lorbeer B, Deinhardt F: Zunahme der Prävalenz von Antikörpern gegen LAV/ HTLV III bei Drogenabhängigen in der Bundesrepublik Deutschland. DMW (1986) 111: 567–570CrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1991

Authors and Affiliations

  • J. Pont
    • 1
  • C. Neuwald
    • 1
  • G. Salzner
    • 1
  1. 1.Sonderanstalt Wien-FavoritenWienAustria

Personalised recommendations